Dogwood Therapeutics (DWTX) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Dogwood Therapeutics (DWTX) has outperformed Tevogen (TVGN) over the past year, losing 77.9% versus a loss of 80.5%. Dogwood Therapeutics is the larger company by market cap ($47.9 million vs $46.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DWTX | TVGN |
|---|---|---|
| Share price | $1.41 | $7.06 |
| Market cap | $47.93M | $45.97M |
| 1-day change | -1.40% | +8.78% |
| YTD return | -66.11% | -57.34% |
| 1-year return | -77.90% | -80.50% |
| 5-year return | -98.80% | — |
| P/E ratio (TTM) | 0.64 | — |
| EPS (TTM) | $2.20 | $-6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.04 | $39.00 |
| 52-week low | $1.28 | $3.64 |
| Distance from 52-week high | -79.98% | -81.90% |
| Analyst consensus | none | — |
| Avg. price target upside | +892.91% | — |
| Average volume | 63.50K | 10.03K |
| Shares outstanding | 33.99M | 6.51M |
| Employees | 8 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Dogwood Therapeutics
DWTX stock →Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
DWTX vs TVGN FAQ
Which is bigger, Dogwood Therapeutics or Tevogen?
Dogwood Therapeutics (DWTX) is larger, with a market capitalization of $47.93M compared with $45.97M for Tevogen (TVGN).
Which stock has performed better over the past year, DWTX or TVGN?
DWTX returned -77.90% over the past 12 months, compared with -80.50% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are Dogwood Therapeutics and Tevogen in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Dogwood Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Tevogen.